LIMN
Liminatus Pharma, Inc. Class A Common Stock
NASDAQ: LIMN · HEALTHCARE · BIOTECHNOLOGY
$0.20
-0.15% today
Updated 2026-04-30
Market cap
$9.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.43
Dividend yield
—
52W range
$0 – $34
Volume
5.0M
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| R&D | $3.80M | $1.85M | $3.76M | $2.69M | $0.00 |
| SG&A | $197000.00 | $856000.00 | $1.06M | $645000.00 | $2.97M |
| Operating income | $-2.53M | $-2.71M | $-2.59M | $-2.91M | $-2.97M |
| Operating margin | — | — | — | — | — |
| EBITDA | $4.37M | $-2.71M | $-1.09M | $-2.75M | $-9.99M |
| EBITDA margin | — | — | — | — | — |
| EBIT | — | — | — | — | $-9.99M |
| Interest expense | — | $219000.00 | $175000.00 | $138102.00 | $215903.00 |
| Income tax | — | $539823.00 | $33987.00 | $18841.00 | — |
| Effective tax rate | 0.0% | -22.6% | -2.9% | -0.7% | 0.0% |
| Net income | $4.37M | $-2.93M | $-1.23M | $-2.90M | $-10.21M |
| Net income growth (YoY) | — | -167.0% | +58.1% | -136.9% | -251.4% |
| Profit margin | — | — | — | — | — |